Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.71 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935074 | 0.91 | XDH (0.78) | XDHGDAPOLA1 | |
| SCHEMBL6751934 | 0.85 | XDH (0.71) | XDHGDA | |
| SCHEMBL667798 | 0.85 | XDH (0.84) | XDHGDAPOLA1 | |
| SCHEMBL9806979 | 0.85 | XDH (0.71) | XDHGDA | |
| SCHEMBL9960821 | 0.84 | XDH (0.69) | XDHGDAPOLA1 | |
| SCHEMBL6272738 | 0.83 | XDH (1.00) | XDHGDAPOLA1 | |
| SCHEMBL17274775 | 0.83 | XDH (0.76) | XDHGDA | |
| SCHEMBL874738 | 0.82 | XDH (0.74) | XDHGDAPOLA1 | |
| SCHEMBL7173183 | 0.82 | XDH (0.66) | XDHGDA | |
| SCHEMBL766669 | 0.82 | XDH (0.66) | XDHGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107903267-B | Azo aromatic nitrogen mustard-chloroethyl nitrosourea coupled compound, preparation method and application | 北京工业大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-108484604-B | Azo aromatic nitrogen oxide-chloroethyl nitrosourea coupling molecule targeting tumor hypoxia, and preparation method and application thereof | 北京工业大学 | 2020-01-17 | — | — | CN | disclosed |
| CN-107903267-A | A kind of compound and preparation method and application of the coupling of azo aryl nitrogen mustard chlorethylnitrosourea | 北京工业大学 | 2018-04-13 | — | — | CN | disclosed |
| CN-107722010-A | A kind of hypoxemia activation chlorethylnitrosourea containing nitroimidazole group and its preparation method and application | 北京工业大学 | 2018-02-23 | — | — | CN | disclosed |
| WO-2017223254-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-28 | — | — | WO | disclosed |
| CN-105503874-B | Hypoxemia activates joint chloroethylnitrosoureas compound and preparation method and application | 北京工业大学 | 2017-10-27 | — | — | CN | disclosed |
| CN-105367573-B | AGT protein inhibitors, its preparation method and application | 北京工业大学 | 2017-07-14 | — | — | CN | disclosed |
| EP-1897882-B1 | N2-QUINOLYL OR ISOQUINOLYL SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | ZHE JIANG MEDECINE CO LTD XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-12-10 | — | — | EP | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1897882-A1 | N2-QUINOLYL OR ISOQUINOLYL SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | Zhe Jiang Medecine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2008-03-12 | — | — | EP | disclosed |
| CN-100355886-C | nucleotide chain modification method | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2007-12-19 | — | — | CN | disclosed |
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| CN-1780909-A | nucleotide chain modification method | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2006-05-31 | — | — | CN | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6635677-B2 | Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea | CASE WESTERN RESERVE UNIVERSITY | 2003-10-21 | — | — | US | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | UNG, TOP2A, OGG1 | XDH 2763/4885GDA 73/4885POLA1 90/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | XDH 2763/4885GDA 73/4885POLA1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.